Insulet Corporation (PODD)
Health Care · $9.7B market cap · SEC CIK 0001145197
fundamentals score out of 100
Next reports on Nov 4, 2026, with analysts expecting $1.62 in earnings per share.
The case for PODD
- Revenue up 29.4% on the year.
- Earnings per share up 66.8%.
- A PEG of 0.39: a P/E of 25.9× is low for EPS growing 67%.
- Has compounded revenue at 24.5% a year over five years.
- Return on equity of 17%.
- Gross margin of 71% absorbs cost shocks.
The case against
- Down 57.5% over the past year.
- Near the bottom of its 52-week range, 61% below the high. Falling prices usually have a reason; find it first.
- Stability is weak (38/100): beta 1.08, a 64% swing over the year.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 44 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 92 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 69 |
| Momentumhow the price has behaved lately | 17 |
| Stabilityhow violently it moves, what it owes and what it pays you | 38 |
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
Key numbers
| Price / earnings | 25.9× |
|---|---|
| Price / book | 13.20× |
| Price / sales | 3.2× |
| Revenue growth (YoY) | +29.4% |
| EPS growth (YoY) | +66.8% |
| Gross margin | 71% |
| Operating margin | 17% |
| Net margin | 12% |
| Return on equity | 17% |
| Debt / equity | 0.63× |
| Current ratio | 2.81 |
| Dividend yield | none |
| Beta | 1.08 |
| 52-week range | $126.40 – $354.88 |
| Position in that range | 6% of the way up |
| 3-month return | -3.6% |
| 1-year return | -57.5% |
Five years of financials, as filed
Pulled from Insulet Corporation's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $2.7B | $2.1B | $1.7B | $1.1B | $1.0B |
| Gross profit | $1.9B | $1.4B | $1.2B | $806M | $752M |
| Operating income | $474M | $309M | $220M | $37.6M | $126M |
| Net income | $247M | $418M | $206M | $4.6M | $16.8M |
| Operating cash flow | $569M | $430M | $146M | $119M | -$68.1M |
| Capital expenditure | $192M | $125M | $75.6M | $123M | $112M |
| Total assets | $3.2B | $3.1B | $2.6B | $2.3B | $2.0B |
| Total liabilities | $1.7B | $1.9B | $1.9B | $1.8B | $1.5B |
| Shareholder equity | $1.5B | $1.2B | $733M | $476M | $556M |
| Cash | $716M | $953M | $704M | $690M | $806M |
| Long-term debt | — | — | — | $1.4B | $1.2B |
| Free cash flow | $378M | $305M | $70.1M | -$3.9M | -$180M |
| Gross margin | 71.6% | 69.8% | 68.3% | 76.3% | 72.3% |
| Operating margin | 17.5% | 14.9% | 13.0% | 3.6% | 12.1% |
| Net margin | 9.1% | 20.2% | 12.2% | 0.4% | 1.6% |
| Diluted shares | 71.9M | 73.9M | 73.6M | 69.9M | 68.6M |
Share count is up 4.8% over 4 years. Mild issuance.
What Insulet Corporation says it does
Overview Insulet Corporation ("we" or the "Company") is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod ® 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH ® Insulin Management System ("Omnipod DASH"), and the Omnipod Insulin Management System ("Classic Omnipod"). We also produce pods for Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. Market Opportunity: Management of Diabetes Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. Glucose, the primary source…
Risk factors PODD lists in its 10-K
- Opinions on the financial statements and internal control over financial reporting
- Definition and limitations of internal control over financial reporting
- Variable consideration – Provision for rebates
- (in millions, except share and per share data)
- Accumulated Other Comprehensive Income (Loss)
- Cash flows from operating activities
- Cash flows from investing activities
- Cash flows from financing activities
- Net (decrease) increase in cash, cash equivalents, and restricted cash
- Cash, cash equivalents, and restricted cash, beginning of year
- Cash and cash equivalents, end of year
- Supplemental cash flow information (Notes
- Note 2. Summary of Significant Accounting Policies
- Accounts Receivable and Allowance for Credit Losses